Predictors of poor outcome in patients diagnosed with drug-resistant tuberculosis in the Torres Strait / Papua New Guinea border region

Foster, J^{1,2,3}¶,#a., Mendez, D³¶., Marais, B⁴&., Peniyamina, D⁵&., McBryde, E.S.^{1,2,3}¶,#b

¹James Cook University College of Medicine and Dentistry, Townsville, Queensland, Australia

²Torres and Cape Tuberculosis Control Unit, Thursday Island, Queensland, Australia

³Australian Institute of Tropical Health and Medicine, Townsville, Queensland, Australia

⁴ Sydney Institute for Infectious Diseases and Biosecurity, Westmead, New South Wales, Australia

⁵Cairns Tropical Public Health Service, Cairns, Queensland, Australia

^{#a}Current address: James Cook University College of Medicine and Dentistry, Townsville, Queensland, Australia

^{#b}Current address: James Cook University College of Medicine and Dentistry, Townsville, Queensland, Australia

*Corresponding author

E-mail: jbelle.foster@my.jcu.edu.au (JF)

[¶]These authors contributed equally to this work [&]These authors also contributed equally to this work

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

ABSTRACT

Drug-resistant tuberculosis (DR-TB) is an ongoing challenge in the Torres Strait / Papua New Guinea border region. Treatment success rates have historically been poor for patients diagnosed with DR-TB, leading to increased transmission and resistance multiplication risk. This study aimed to identify predictors of poor outcome in patients diagnosed with DR-TB to inform programmatic improvements.

A retrospective study of all DR-TB cases who presented to Australian health facilities in the Torres Strait between 1 March 2000 and 31 March 2020 was performed. This time period covers four distinct TB programmatic approaches. Univariate and multivariate predictors of poor outcome were analysed. Poor outcome was defined as treatment default, treatment failure and death (versus cure or completion).

In total, 133 patients with resistance to at least one TB drug was identified. The vast majority (123/133; 92%) of DR-TB patients had pulmonary involvement; and of these, 41% (50/123) had both pulmonary and extrapulmonary TB. Poor outcomes were observed in 29% (39/133) of patients. Patients living with human immunodeficiency virus, renal disease or diabetes (4/133; 4/133; 3/133) had an increased frequency of poor outcome (p < 0.05), but numbers were very small. Among all 133 DR-TB patients, 41% had a low lymphocyte count, which was significantly associated with poor outcome (p < 0.05). Overall, outcome improved in recent years with a 50% increase in the chance of a good outcome per year group over the study period; on binary logistic regression analysis. Being a close contact of a known TB case was associated with improved outcome.

While DR-TB treatment outcomes have improved over time, it remains important to prevent DR-TB spread and resistance multiplication resulting from suboptimal treatment. Enhanced surveillance for DR-TB, better cross border collaboration and consistent diagnosis and management of comorbidities and other risk factors should further improve patient care and outcomes.

Introduction:

Drug resistance is a significant threat to control of tuberculosis (TB), with nearly half a million of the ten million cases in 2019 estimated to be rifampicin resistant (1). Drug-resistant (DR)-TB refers to TB strains that are resistant to any of the first-line drugs used to treat fully-susceptible (FS)-TB, any of the second-line drugs used to treat DR-TB, or are resistant to a combination of these drugs (2). Non-compliance or inadequate FS-TB treatment regimens may lead to the development of DR-TB and multidrug-resistant (MDR)-TB – that which is resistant to both isoniazid and rifampicin - which is substantially more difficult and costly to treat (3). Treatment outcomes are generally worse for DR-TB cases due to prolonged treatment regimens and severe adverse effects of TB drugs (4). Globally, the average treatment success rate in patients with MDR-TB is reported to be 50% (5) however this varies across countries (Ukraine – 18.1% (6); China – 52.2% (7); Ethiopia – 78.6%) (8).

TB is an ongoing threat in the Torres Strait / Papua New Guinea (PNG) region which is compounded by high levels of DR-TB in the Western Province of PNG and in particular, on Daru Island (9, 10) (Fig 1). The conservative incidence rate of TB in PNG is 432 / 100,000 population (WHO, 11) and 674 / 100,000 in the Western Province (12). By comparison, the incidence rate of TB over the border in Queensland, Australia is 5.5 / 100,000 population (13). In the Torres Strait Islands, 80% identify as Torres Strait Islander (14), and Indigenous Australians are disproportionately affected by TB when compared to non-Indigenous Australians (15). Significantly, residents from specific islands in the Torres Strait and villages in the Western Province of PNG share an open international border (Fig 1), heightening TB transmission risk in the region (10).

Fig 1. Map of the Torres Strait / Papua New Guinea cross-border region (16)¹ CC BY 4.0

¹ International travel without passport or visa is permitted for traditional inhabitants of the Torres Strait Protected Zone and Treaty villages of Papua New Guinea DOI. 10.6084/m9.figshare.16632823

1	Management of DR-TB is complex and is often further complicated by comorbidities with other
2	communicable and non-communicable diseases (17). Patients with TB and coinfection /
3	comorbidities such as renal impairment, diabetes and HIV are more likely to have poor outcomes
4	(18-20). Many studies have reported high rates of mortality in TB patients with comorbidities (21-24)
5	and in patients with low levels of haemoglobin, albumin and lymphocytes (25)
6	While the rise in DR-TB is a global concern, TB programs must consider specific local risk factors and
7	programmatic gaps to ensure better outcomes for patients. These considerations may present
8	important opportunities for TB programmes to meet the challenging targets of the WHO to End TB,
9	aiming to reduce the incidence of TB by 90% before 2035 (26)
10	Little is known about predictors of treatment outcomes in patients diagnosed with DR-TB in the
11	Torres Strait / PNG border region. The aim of this study was to evaluate the association of
12	comorbidities / coinfection, the levels of a suite of serum biomarkers and the impact of
13	programmatic changes to models of TB care over time with treatment outcomes in DR-TB patients
14	diagnosed in the Torres Strait / PNG border region. It is the intention that evidence derived from this
15	study will be carefully considered at a programmatic level to further improve outcomes for patients
16	diagnosed with DR-TB in this context.
17	Methods:
18	Study Design and Population

This is a retrospective cohort study of 133 patients diagnosed with laboratory-confirmed DR-TB
between 2000 and 2020 in the Torres Strait Islands, Australia. Pulmonary, extrapulmonary, smear
positive and smear negative cases were included, as well as those with mono, poly and multidrugresistant TB.

All residents of the Torres Strait Islands and residents of the PNG villages adjacent to the northern
 Australia / PNG border who were diagnosed in the Torres Strait with laboratory-confirmed DR-TB

25 were included in the study. Patients were excluded from the study if they were residents of PNG

- 26 villages external to the Western Province of PNG who did not enter the Australian health system via
- a health facility in the Torres Strait Protected Zone (Fig 1).
- 28 Models of TB Care Diagnosis and Treatment
- 29 There were four models of TB care provided in the region over different time periods between 2000

30 to 2020 (2000-2005; 2006-2012; 2013-2015; 2016-2020). Across all models of TB care, the primary

31 mode of diagnosis was via sputum collection and the collection of specimens for the diagnosis of

32 extrapulmonary TB was rarely available in remote Australian border clinics. Isolation of

33 mycobacterial culture, drug susceptibility testing and genotyping for specimens collected in this

34 region were performed in the Queensland Mycobacterium Reference Laboratory in Brisbane (Fig1).

35 (27). The major differences in care resulting from these changes were reduction in time to treatment

36 commencement and retention in care (28).

37 Between 2000 and 2012, some treatment for DR-TB was available for PNG nationals diagnosed with 38 DR-TB in Australian border clinics, however, access to treatment was improved between 2006 and 39 2012 with the establishment of frequent outreach TB clinics in the Torres Strait. The change from the 40 2000-2005 model of TB care to the 2006-2012 model of TB care was in direct response to Australian 41 Government decisions to invest in TB management of PNG patients from two outer Torres Strait 42 Islands, Boigu and Saibai (29). The 2013-2015 model of TB care is reflective of Government decisions 43 to stand-down these outer island clinics and increase support and funding for TB health service 44 coverage capability in PNG (30), thus PNG residents diagnosed from 2013 onwards were referred back to the PNG health system for treatment and management. Government decisions to invest in a 45 local Torres Strait-based TB Control Unit with the aim of rapid response to suspected and confirmed 46 47 case notifications occurred from 2016 and is ongoing (31). All Australian residents in this study were 48 managed within the Australian healthcare system.

49

50 Data Collection

- 51 Queensland Health's Notifiable Conditions System (NoCS) was used to source case notification data.
- 52 Only cases with laboratory confirmed drug-resistant TB were included in the study, including those
- 53 resistant to streptomycin. One case was added to the study where their drug-resistant status was
- 54 identified in Queensland Health's laboratory software, AUSLAB but was not registered as a drug-
- 55 resistant TB case in NoCS.
- 56 Raw data pertaining to biomarkers (haemoglobin, albumin, lymphocyte levels) were obtained from
- 57 Queensland's laboratory results software, AUSLAB. These biomarkers are routinely collected in most
- 58 patients presenting to primary healthcare facilities in the Torres Strait.

59 Definitions

- 60 Treatment outcome definitions used in the study were as per Laserson et al. (32). Poor treatment
- outcome was defined as death, default or treatment failure. Good treatment outcome was defined
- 62 as completed treatment or cured. Other treatment outcome was defined as transfer out, to indicate
- 63 that the patient had been referred back to the PNG health system. In some patients that were
- 64 transferred out, treatment outcome was unknown.
- 65 Comorbidities / coinfection were defined as HIV, diabetes and renal impairment. In patients with
- 66 comorbidities recorded as renal dysfunction, renal insufficiency, renal disease and renal failure were
- 67 all defined as having renal impairment.
- 68 Site of disease included pulmonary TB, extrapulmonary TB or both. Case type refers to either newly
- 69 diagnosed TB cases as well as those who had previously received full or partial treatment.

70 Data Analyses

- 71 Statistical analyses were performed using IBM SPSS Statistics, version 25 (2019, Armonk, New York,
- 72 United States). Frequencies and percentages were calculated for descriptive data including age
- categories, sex, country of birth, visa status, primary health centre (PHC) attended, programmatic

diagnosis year group (Fig 2), site of disease, case type, comorbidities/coinfection, drug resistance,
cough and known close contact status. Pearson's Chi-squared tests were carried out to assess
whether age group, sex, country of birth, visa status, and PHC attended were associated with poor
treatment outcomes.

78 Potential categorical predictors (site of disease, HIV serology, case type, comorbidities/coinfection, 79 drug resistance and selected biomarkers including haemoglobin, lymphocytes and albumin), were 80 analysed by poor, good or unknown treatment outcome using Fisher's Exact or likelihood ratios, 81 except for ethionamide resistance and lymphocyte levels where Pearson Chi-Square was used to 82 ascertain if there was a statistically significant association between these factors and treatment 83 outcomes. Likelihood ratios, which when compared to Pearson's Chi-squared test are more likely to 84 be Exact, were undertaken to ascertain association with poor treatment outcome for variables with 85 more than one categorical variable. The categorical variable 'diagnostic year group' was included in 86 the analysis as a clinical covariate to account for programmatic changes in the clinical management 87 of TB over time.

Pearson's Chi-squared tests were performed to assess whether selected biomarkers (haemoglobin, 88 89 lymphocyte and albumin levels) were associated with binary treatment outcomes (poor or other). 90 Multiple imputation was not used for these analyses and numbers of patients that had biomarkers 91 available were reported. In all univariate and multivariate logistic regression analyses, multiple 92 imputation was applied and pooled results from five imputations were used as 19 DR-TB cases did 93 not have any biomarker results available. Biomarker Z scores were imputed for incomplete variables 94 and were further defined as nominal (poor or other) prior to imputation. To overcome differences in 95 reference range parameters that were automatically applied by Queensland Health's laboratory 96 software, AUSLAB to biomarker results based on sex and age, Z scores were calculated in Microsoft 97 Excel (2016, North Ryde, Australia). With reference to haemoglobin levels, anaemia was defined as 98 those with a Z score at least 2 standard deviations (SD) away from the mean, and severe anaemia

was defined as those with a Z score that was at least 5SD away from the mean. This resulted in our
definition of anaemia fitting with the laboratory definition of below the reference range, for a given
laboratory and patient profile. Similarly, low albumin and lymphocyte levels were defined as those
with a Z score at least 2SD away from the mean.

103 Univariate analysis of comorbidities/coinfection, diagnosis year group, contact with a known case,

biomarkers, acid-fast bacilli (AFB) positivity and rifampicin-resistance were examined as potential

105 predictors of poor outcome using binary logistic regression. All predictor variables were considered

for multivariate regression. The regression method was a forward algorithm with entry criteria of p < 100

107 0.05 from the univariate analyses followed by a backward algorithm with back entry criteria of p >

108 0.05. The level of significance was set at p < 0.05 for all analyses.

109 Ethics

110 The Far North Queensland Human Research Ethics Committee (HREC) (HREC/17/QCH/74-1157)

approved the study, as did the Chair of James Cook University HREC, (H7380). Further approval was

obtained to access case notification data via a Public Health Act application (QCH/36155 – 1157).

113 Results:

Of the 133 patients with DR-TB there were 22 deaths and one failed therapy, 16 defaulted and 51 114 115 were transferred out. Of the 51 that were transferred out, 41 had no known outcome. As shown in 116 Table 1, Boigu Island PHC received fewer patients than Saibai Island PHC but had greater treatment 117 success (49% vs 38%). The median age was 28, and patients in the 15-29 years age group were both 118 the largest group and disproportionately affected by poor outcomes (Table 1). Eighty-three percent 119 of older adults aged \geq 60 years had a poor outcome, and of those >61 years, 100% died. There was no effect of sex on outcome. Being a PNG national rather than an Australian Torres Strait Islander was 120 121 highly predictive of poor outcome.

122 Table 1. Demographic characteristics of all patients diagnosed with drug-resistant tuberculosis in

the Torres Strait Islands between 2000 and 2020, and their association with good, poor and other 123

124 **TB treatment outcomes**

	Treatment Outcomes N = 133 (%) [†]							
Characteristic	Good		Poor		Other		Р	
	Cured	Completed	Died	Failed	Defaulted	Transfer Out	Total	
Age group								.02
<5 years	2 (22)	5 (56)	0 (0)	0 (0)	0 (0)	2 (22)	9	
5-14 years	1 (10)	3 (30)	1 (10)	0 (0)	2 (20)	3 (30)	10	
15-29 years	3 (5)	21 (34)	10 16)	0 (0)	10 (16)	18 (29)	62	
30-44 years	6 (18)	9 (27)	5 (15)	0 (0)	4 (12)	9 (27)	33	
45-59 years	0 (0)	2 (15)	2 (15)	0 (0)	0 (0)	9 (70)	13	
≥ 60 years	1 (17)	0 (0)	4 (67)	1 (17)	0 (0)	0 (0)	6	
Gender								.7
Female	9 (12)	22 (30)	14 (19)	1 (1)	8 (11)	21 (28)	75	
Male	4 (7)	18 (31)	8 (14)	0 (0)	8 (14)	20 (35)	58	
Country of Birth								.02
Australia	3 (50)	2 (33)	1 (17)	0 (0)	0 (0)	0 (0)	6	
Papua New Guinea	10 (8)	38 (30)	21 (17)	1 (1)	16 (13)	41 (32)	`127	
Visa Status								.002
Australian resident	3 (33)	3 (33)	2 (22)	1 (11)	0 (0)	0 (0)	9	
Papua New Guinea Treaty Visitor	5 (6)	23 (27)	15 (17)	0 (0)	13 (15)	30 (35)	86	
Papua New Guinea non-Treaty Visitor	5 (13)	14 (37)	5 (13)	0 (0)	3 (8)	11 (29)	38	
Primary Health Centre Attended								.98
Saibai Island	11 (10)	32 (29)	19 (17)	1 (1)	14 (13)	33 (30)	110	
Boigu Island	2 (13)	7 (44)	2 (13)	0 (0)	2 (13)	3 (19)	16	
Murray Island	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (100)	2	
Darnley Island	0 (0)	1 (50)	0 (0)	0 (0)	0 (0)	1 (50)	2	
Yorke Island	0 (0)	0 (0)	1 (50)	0 (0)	0 (0)	1 (50)	2	
Thursday Island	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (100)	1	

125 ⁺ Percentages may not equal 100 due to rounding.

127	Table 2 shows that DR-TB patients diagnosed between 2000 and 2005 were more likely to have poor
128	outcomes (50%) than those diagnosed between 2016 and 2020 (17%). Of 133 cases of DR-TB, 67%
129	had MDR-TB and of those, 74% (n = 66) were new cases and 32% had a poor outcome. Ethionamide
130	resistance was only identified in patients diagnosed with MDR-TB (p <.001) and 90% of MDR-TB
131	cases were ethionamide resistant. Nearly one in five patients had previously received full or partial
132	treatment in Australia or PNG. The composite variable for comorbidities/coinfection were comprised
133	of four DR-TB / HIV coinfection cases, three DR-TB / diabetes comorbidity cases and four DR-TB /
134	renal comorbidity cases. Seventy-five percent of patients with DR-TB/HIV coinfection died, and 100%
135	of patients with DR-TB/diabetes comorbidity died. Overall, 78% of patients with DR-TB and at least

136 one coinfection/comorbidity had a poor outcome.

137 Table 2. Clinical variables of patients diagnosed with drug-resistant tuberculosis in the Torres

138 Strait between 2000 and 2020, and their association with good, poor and other TB treatment 139 outcome

	Treat				
Variable	Poor (N = 39; 29%)	Good (N = 53; 40%)	Other (N = 41; 31%)	Total	Р
Diagnosis Year Group*				133	.045
2000-2005	7 (50)	5 (36)	2 (14)	14	
2006-2012	26 (27)	37 (39)	33 (34)	96	
2013-2015	4 (36)	2 (18)	5 (46)	11	
2016-2020	2 (17)	9 (75)	1 (8)	12	
Disease Site				133	.08
Pulmonary TB	25 (34)	22 (30)	26 (36)	73	
Extrapulmonary TB	2 (20)	7 (50)	1 (10)	10	
Both PTB and XPTB	12 (24)	24 (48)	14 (28)	50	
Case Type				133	.2
New	29 (27)	41 (38)	37 (35)	107	
Full or partial treatment overseas	8 (38)	11 (52)	2 (10)	21	
Full or partial treatment in Australia	2 (40)	1 (20)	2 (40)	5	
Comorbidities / Coinfection				133	.003
Diabetes Mellitus, Renal Disease or HIV	7 (78)	0	2 (22)	9	
No known risk factors	32 (26)	53 (43)	39 (32)	124	

Drug Resistance				133	.04
Isoniazid (mono)	5 (14)	16 (46)	14 (40)	35	
Rifampicin (mono)	3 (75)	1 (25)	0	4	
MDR-TB	29 (33)	33 (37)	27 (30)	89	
Other (streptomycin mono)	2 (40)	3 (60)	0	5	
Ethionamide				133	.8
Ethionamide resistant	24 (30)	30 (38)	26 (33)	80	
Susceptible	15 (28)	23 (43)	15 (28)	53	
Cough				114	.1
Cough	27 (31)	31 (36)	29 (33)	87	
No cough	4 (15)	15 (56)	8 (30)	27	
Close Contact [#]				133	.02
Close contact	8 (16)	23 (45)	20 (39)	51	
No known contact	31 (38)	30 (37)	21 (26)	82	

140 Note. poor outcome - died, failed, defaulted; good outcome - cured, completed treatment; other -

141 transferred out

*Diagnosis year group was included as a variable due to changes in the clinical management of DR-

- 143 TB patients over time.
- 144 #Close contact to a known TB case as reported by patient.
- 145 PTB, pulmonary TB; XPTB, extrapulmonary TB; MDR-TB, multidrug-resistant TB.
- 146 Table 3 shows that 86% of patients with haemoglobin recorded had anaemia, and of those, 38% had
- severe anaemia. Low albumin was detected in 76% of patients that had levels recorded. In patients
- 148 with low lymphocyte levels, 44% of patients had a poor outcome.

149 Table 3. Blood test abnormalities in patients diagnosed with drug-resistant tuberculosis in the

150 Torres Strait between 2000 and 2020, and their association with treatment outcome

Verieble	Treatment Outcome n (%)						
Variable	Poor	Other	Total	Р			
Haemoglobin Levels* (50-146L)			107	.5			
No anaemia	3 (20)	12 (80)	15				
Mild anaemia	20 (35)	37 (65)	57				
Severe anaemia	10 (29)	25 (71)	35				
Lymphocyte count# (0.04-9.80L)			106	.01			
Normal	13 (21)	50 (79)	63				
Low	19 (44)	24 (56)	43				
Albumin [#] (<15-48L)			105	.07			

Other (normal or high)	4 (16)	21 (84)	25	
Low	28 (35)	52 (65)	80	

*Mild anaemia, at least 2 standard deviations (SD) away from the mean; severe anaemia, at least

152 5SD away from the mean; [#]Low lymphocyte and albumin, at least 2SD away from the mean.

153 In Table 4, patients with comorbidities / coinfection, low lymphocyte levels and AFB positivity were

154 significantly more likely to have poor outcomes. Being a close contact of a known TB case was a

protective factor and reduced the odds of a poor outcome occurring (*p*.008; OR.31). Although the p

value for anaemia in Table 3 was > .1, this variable was included in the univariate analysis as other

157 studies have demonstrated an association between anaemia and poor outcomes (33), however in

this study, anaemia was not a significant predictor of poor outcomes. In the adjusted multivariate

159 model, comorbidities / coinfection, being a close contact of a known TB case and low lymphocyte

160 levels retained significance (p < 0.05).

161Table 4. Predictors of poor treatment outcome among drug-resistant tuberculosis cases diagnosed162in the Torres Strait / Papua New Guinea border region between 2000 and 2020 (n = 133)

Variable		Univariate Analysis		Multivariate Analysis		
	N (%)	OR (95% CI)	p-value	aOR (95% CI)	p-value	
Comorbidities / Coinfection (DM, renal, HIV)	9 (7)	10.06 (1.98-50.96)	.005	17.4 (2.6-117.06)	.003	
Contact with known TB case	51 (38)	.31 (.1273)	.008	.3 (.0887)	.03	
Low lymphocyte level	43 (32)	3.05 (1.29-7.17)	.01	2.7 (1.1-7.08)	.04	
AFB positive	80 (60)	2.4 (1.07-5.58)	.03	1.6 (.56-4.48)	.4	
Rifampicin resistance	93 (70)	2.5 (.96-6.21)	.05	Eliminated at forward step		
Anaemia	93 (70)	1.9 (.50-7.26)	.3	Eliminated at forward step		
Low albumin level	80 (60)	2.8 (.88-9.05)	.08	Eliminated at forward step		
Female sex	75 (56)	1.2 (.55-2.47)	.7	Eliminated at forward step		

163 Note. aOR, adjusted odds ratio; CI, confidence interval; DM, diabetes mellitus; renal, renal

164 impairment; HIV, human immunodeficiency virus; AFB, acid-fast bacilli.

165 **Discussion:**

166 This is the first study, to the best of our knowledge, to identify predictors of poor treatment 167 outcomes in patients diagnosed with DR-TB and examine the impact of four different models of TB 168 care over two decades in the Torres Strait / PNG border region. We found a 50% improvement in 169 good treatment outcomes under the model of care involving a local TB unit from 2016 compared 170 with earlier models. Patients diagnosed before 2013 were significantly more likely to have poor 171 treatment outcomes in this study and this is reflective of a time when accessibility to mycobacterial 172 culture and drug susceptibility testing was not routinely available on Daru Island in PNG, and where 173 access to second line drugs was only available for PNG nationals in this study via Australian TB clinics 174 (34). For patients diagnosed between 2013 and 2015 in this study, a higher proportion had an 175 unknown outcome. This is consistent with the changeover from the 2006 to 2012 TB management 176 model of increased surveillance and detection at border clinics, to a handover period whereby PNG 177 patients diagnosed at Australian border health facilities were referred back to the PNG health 178 system for ongoing management and care.

179 From 2016 onwards, TB clinicians were based in the Torres Strait and therefore able to rapidly 180 respond to cases diagnosed, associated contact tracing efforts and monitoring of treatment 181 compliance and outcomes for patients. Higher success rates for DR-TB patients have been reported in countries where patients have access to developed health infrastructure and where skilled 182 183 clinicians are positioned to support DR-TB patients (35). From 2016, local nurses and Indigenous 184 Health Workers undertook Directly Observed Therapy for TB patients residing in the Torres Strait. 185 Collegial relationships between TB programs in the Torres Strait and Daru Island were also 186 strengthened through this period with the joint development of procedural documents and 187 processes (36) which enabled each TB program to define data requirements, streamline the 188 exchange of shared patient information, and enhance surveillance capability. These initiatives are 189 consistent with the Australian National Tuberculosis Advisory Committee recommendations to 190 engage in regional and bilateral collaborations in order to improve TB services in high-risk areas (37).

191 This study also found that close contacts of previous TB cases were afforded a protective factor 192 against poor treatment outcomes. It is widely accepted that household contacts of DR-TB patients 193 are at greater risk of exposure, infection and disease progression when compared with other types 194 of contacts (38). In a study of MDR-TB index cases in Pakistan, MDR-TB diagnoses were reported in 195 17.4% of close contacts (38). Unlike isoniazid-resistant TB which is more amenable to treatment, 196 patients with both isoniazid and rifampicin resistance may be more likely to remain infectious longer 197 than patients with DS-TB (39), thus increasing the likelihood of transmission to close contacts. Despite the increased transmission risk, close contacts had more favourable outcomes in this study. 198 199 A possible explanation is that these close contact patients were linking in with healthcare services 200 earlier, perhaps while accompanying previously diagnosed household members to clinic 201 appointments. Better outcomes for close contacts after 2014 may also be attributed to improved 202 health literacy and symptom recognition as a result of mass community education offered in the 203 region from 2014 (40). 204 A limitation in this study is that it did not identify the type of close contact (i.e. household contact), 205 nor ascertain the type of TB that each close contact was exposed to. The recent upgrade of the 206 Mabadauan health centre in PNG will aid the PNG health system's capacity to manage close contacts 207 in border communities. It will, however, be important that expanded diagnostic capabilities at 208 Mabadauan, are matched with capacity to retain patients in the TB care pathway (35). Since 2016, 209 the Torres and Cape TB Control Unit has collected and shared TB contact tracing data with Daru 210 General Hospital, related to all PNG residents diagnosed with TB in the Torres Strait. It is anticipated 211 that increased capacity of local health services available to residents of PNG living adjacent to the 212 Torres Strait, may lead to effective TB contact management, further improve treatment outcomes 213 for PNG patients diagnosed with DR-TB as well as support TB patients with other 214 comorbidities/coinfection.

Another potential limitation of this study is that only people with TB isolates with at least one
frontline drug resistance was included. Hence the full impact of MDR treatment (compared with fully
susceptible TB) could not be evaluated. We were however able to compare those with and without
rifampicin resistance, finding a trend to worse outcome.

219 Patients with pre-existing comorbidities/coinfection in this study were significantly more likely to 220 have poor treatment outcomes. This finding is consistent with that of other studies that report 221 worse treatment outcomes for patients with comorbidities/coinfection (6, 41, 42). In our study, no 222 patients with a reported comorbidity/coinfection were cured or completed treatment. One hundred 223 percent of patients with DR-TB/diabetes comorbidity died and 75% of patients with TB/HIV 224 coinfection had a poor outcome, and this is cause for concern. While HIV is a very strong predictor 225 for the development of active TB disease, HIV is unlikely to be a major contributing factor in TB 226 transmission dynamics in the region as currently less than 1% of the population is infected (43). 227 Regardless, the high proportion of poor treatment outcomes in patients with TB/HIV coinfection 228 suggests routine HIV testing is warranted for all patients diagnosed with TB in this setting. It is also 229 possible that 'stand-alone' or vertical disease programs of TB control, diabetes management and 230 sexual health in the current health system may contribute to poor outcomes for coinfected patients 231 (44). To help mitigate poor outcomes in patients with DR-TB/diabetes and DR-TB/HIV coinfection, it 232 may be beneficial for TB programs to establish linkages with both diabetes educators and sexual 233 health providers to provide enhanced screening, monitoring and management of patients with these 234 comorbidities / coinfection (45). As there were no protocols in places to consistently screen TB 235 patients for diabetes or renal impairment during this study period, it is possible that comorbidities 236 have been under-reported in this study.

Aboriginal and Torres Strait Islander peoples develop chronic kidney disease three times as often as non-Indigenous Australians (46) and in Torres Strait Islander adults, a recent survey found that nearly one in five people showed signs and symptoms of chronic kidney disease (47). In renal

patients, delayed diagnosis of TB is a possible reason for poor prognosis (24). As uremic symptoms
like fever and weight loss are non-specific symptoms of both TB and renal disease, renal physicians
would be well placed to consider TB as a differential diagnosis and monitor patients with insidious
onset of these symptoms (24). Early detection of TB in renal patients may be key to improved
outcomes (24). Efforts to increase collaboration between renal and TB units in the Torres Strait may
help reduce diagnostic delay and better support shared patients.

246 In this study, we also evaluated low serum haemoglobin, albumin and lymphocyte levels as 247 predictors of poor outcomes of DR-TB. Our findings show that low lymphocyte levels are statistically 248 significantly associated with poor treatment outcomes in DR-TB patients, consistent with other 249 studies (48). In patients that have had TB for sustained periods such as those with previous 250 treatment default or failure, overall health decline evidenced by low lymphocyte levels can be a 251 marker for severity of TB disease which can be more complex to manage (49). When compared to 252 FS-TB, lower lymphocyte counts have been reported in MDR-TB patients (50). Low lymphocyte 253 levels, AFB positivity, and skewed distribution of low haemoglobin and low albumin levels in DR-TB 254 cases, are all representative of poor health at diagnostic baseline, as were observed in this study. 255 In other studies, serum haemoglobin and albumin were strong predictors of mortality (51) and in 256 China and Israel, an association between hypoalbuminaemia and poor prognosis in DR-TB patients 257 has been reported (7, 52). Further, a study conducted in Ethiopia reported that MDR-TB patients 258 with low haemoglobin levels (anaemia) were more than twice as likely to have poor treatment 259 outcomes when compared to patients without anaemia (41). Although anaemia and 260 hypoalbuminaemia were not statistically significantly associated with poor outcomes for DR-TB 261 patients in this study, it is unlikely that this was due to clinical manifestations of disease and more 262 likely a power issue as nearly all patients in this study were anaemic and hypoalbuminaemic. Low 263 haemoglobin has been associated with poor outcomes in TB patients, as well as delayed sputum 264 conversion at two months (53). This may help to explain the significant association in this study

between poor outcomes and patients with AFB positive DR-TB, although this study did not examine
timing of sputum conversion. It is possible that the cause of anaemia in DR-TB patients is due to iron
nutritional deficiency (33), however this study did not explore levels of iron, ferritin, hepcidin and

268 transferrin.

269 Limitations

270 Our study has several limitations, some of which have been described above. Additionally, this study

271 only included DR-TB patients which may have impacted the power of statistical analyses. Future

studies could incorporate drug-susceptible patients in the same periods to use as a comparator. We

273 were unable to ascertain whether the cause of death for all patients was TB, however, patient death

was documented during the time period for the course of TB treatment for all patients.

275 Conclusion

276 Although having a locally-based TB program in the Torres Strait has resulted in better treatment 277 outcomes for DR-TB patients, interventions to both reduce the likelihood of poor outcomes and refine the focus on maximising treatment completion in vulnerable sub-population groups at risk of 278 poor outcomes are needed. Comorbidities and poor health indicators at diagnosis show that DR-TB 279 280 is occurring in vulnerable populations. These findings have important implications for TB programs 281 on both sides of this international border where DR-TB is prevalent, and there are multiple operational modifications worth consideration. Routine incorporation of key strategies should 282 283 include collaborative working relationships with diabetes/renal/sexual health care providers to 284 consistently identify and manage TB in patients with comorbidities, enhanced cross border 285 collaboration and ongoing commitment to point of care HIV and baseline blood testing that may 286 help to flag DR-TB patients at-risk of poor outcomes.

287

288

289 REFERENCES

290 1. World Health Organization. Global tuberculosis report. Geneva, Switzerland: World Health 291 Organization; 2020.

292 World Health Organization (WHO). WHO treatment guidelines for drug-resistant 2. 293 tuberculosis. Geneva, Switzerland: World Health Organization; 2016.

294 Jenkins HE, Crudu V, Soltan V, Ciobanu A, Domente L, Cohen T. High risk and rapid 3. 295 appearance of multidrug resistance during tuberculosis treatment in Moldova. European Respiratory 296 Journal. 2014;43:1132-41.

297 Sagwa E, Ruswa N, Musasa JP, Mantel-Teeuwisse AK. Adverse events during treatment of 4. 298 drug-resistant tuberculosis: A comparison between patients with or without human 299 immunodeficiency virus co-infection. Drug Safety. 2013;36:1087–96.

300 5. Nair D, Velayutham B, Kannan T, Tripathy JP, Harries AD, Natrajan M, et al. Predictors of 301 unfavourable treatment outcome in patients with multidrug-resistant tuberculosis in India. Public 302 Health Action. 2017;7(1):32-8.

303 6. Aibana O, Bachmaha M, Krasiuk V, Rybak N, Flanigan TP, Petrenko V, et al. Risk factors for 304 poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine. Biomed Central 305 Infectious Diseases. 2017;17(129).

306 Tang S, Tan S, Yao L, Li F, Li L, Guo X, et al. Risk Factors for Poor Treatment Outcomes in 7. 307 Patients with MDR-TB and XDR-TB in China: Retrospective Multi-Center Investigation. PLOS ONE. 308 2013;8(12).

309 Meressa D, Hurtado RM, Andrews JR, Diro E, Abato K, Daniel T, et al. Achieving high 8. 310 treatment success for multidrug-resistant TB in Africa: initiation and scale-up of MDR TB care in 311 Ethiopia—an observational cohort study. Biomed Journal Thorax. 2015;70(12).

312 9. Furin J, Cox H. Outbreak of multidrug-resistant tuberculosis on Daru Island. Lancet 313 Respiratory Medicine. 2016;4(5):347-9.

314 Baird T, Donnan, E., Coulter, C., Simpson, G., Konstantinos, A., Eather, G. . Multidrug-10. 315 resistant tuberculosis in Queensland, Australia: an ongoing cross-border challenge. International Journal of Tuberculosis and Lung Disease. 2018;22(2):206-11. 316

317 World Health Organization. TB country profile - Papua New Guinea. Geneva, Switzerland: 11. 318 World Health Organization; 2016.

319 Aia P, Wangchuk L, Morishita F, Kisomb J, Yasi R, Kal M, et al. Epidemiology of tuberculosis in 12. 320 Papua New Guinea: analysis of case notification and treatment-outcome data, 2008-2016. Western 321 Pacific Surveillance and Response Journal. 2018;9(2):9-19.

322 Viney K. The Australian tuberculosis risk factor survey Canberra, Australia: Australian 13. 323 National University; 2021.

324 14. Australian Bureau of Statistics. Changing characteristics of the Torres Strait region and its 325 people. Canberra, Australia: Australian Bureau of Statistics,; 2018.

326 15. Robertus LM, Konstantinos A, Hayman NE, Paterson DL. Tuberculosis in the Australian indigenous population: History, current situation and future challenges. Australian and New Zealand 327 328 Journal of Public Health. 2011;35(1):6-9.

329 16. Moran M, Foster J, Mendez D, cartographers. Map of the Torres Strait / Papua New Guinea 330 cross-border region. Cairns, Queensland 2021. DOI. 10.6084/m9.figshare.16632823.

331 17. Esmail A, Sabur NF, Okpechi I, Dheda K. Table Bloods. Biomarkers in patients diagnosed with drug-resistant TB in the Torres Strait between 2000 and 2020, stratified by treatment outcome. 332 333 Journal of Thoracic Disease. 2018;10(5).

334 18. Chung-Delgado K, Guillen-Bravo S, Revilla-Montag A, Bernabe-Ortiz A. Mortality among 335 MDR-TB Cases: Comparison with Drug-Susceptible Tuberculosis and Associated Factors. PLOS ONE. 336 2015;10(3).

Bhering M, Duarte R, Kritski A. Predictive factors for unfavourable treatment in MDR-TB and 337 19. 338 XDR-TB patients in Rio de Janeiro State, Brazil, 2000-2016. PLOS ONE. 2019;14(11).

339 20. Gómez-Gómez A, Magaña-Aquino M, López-Meza S, Aranda-Álvarez M, Díaz-Ornelas DE, 340 Guadalupe Hernández-Segura M, et al. Diabetes and Other Risk Factors for Multi-drug Resistant 341 Tuberculosis in a Mexican Population with Pulmonary Tuberculosis: Case Control Study. Archives of 342 Medical Research. 2015;46(2). 343 Lui SL, Tang S, Li FK, Choy BY, Chan TM, Lo WK, et al. Tuberculosis infection in Chinese 21. 344 patients undergoing continuous ambulatory peritoneal dialysis. American Journal of Kidney Disease. 345 2001;38:1055-60. 346 22. Taskapan H, Utas C, Oymak FS, Gulmez I, Ozesmi M. The outcome of tuberculosis in patients on chronic hemodialysis. Clinical Nephrology. 2000;54:134-7. 347 348 Moore DA, Lightstone L, Javid B, Friedland JS. High rates of tuberculosis in end-stage renal 23. 349 failure: the impact of international migration. Emerging Infectious Disease. 2002;8:77-8. 350 24. Hussein MM, Mooij JM, Roujouleh H. Tuberculosis and Chronic Renal Disease. Seminars in 351 Dialysis. 2003;16(1):38-44. 352 Rarau P, Guo S, Baptista SN, Pulford J, McPake B, Oldenburg B. Prevalence of non-25. 353 communicable diseases and their risk factors in Papua New Guinea: A systematic review. SAGE Open 354 Medicine. 2020;8. 355 26. World Health Organization (WHO). WHO End TB Strategy. Geneva: Switzerland: World 356 Health Organization; 2015. 357 27. Bainomugisa A, Pandey S, Donnan E, Simpson G, Foster J, Lavu E, et al. Cross-border 358 movement of a highly drug resistant Mycobacterium tuberculosis strain identified in the Torres 359 Strait, Australia. Emerging Infectious Disease 2019;25(3). Foster J, Mendez D, Marais B, Peniyamina D, McBryde ES. Time to commencement of 360 28. 361 effective treatment in patients with drug-resistant tuberculosis diagnosed in the Torres Strait / 362 Papua New Guinea cross-border region. medRxiv. 2022. 363 Vincent SD. A clinician's perspective on providing TB services in the Torres Strait. Medical 29. 364 Journal of Australia. 2011;195(9):506-7. 365 Marais B, Sorrell T, Brittle W. Drug-resistant tuberculosis in PNG and Torres Strait islands. 30. 366 The Conversation. 2012. Queensland Health. Tuberculosis (TB) Control: Torres and Cape Hospital and Health Service; 367 31. 368 2016 [Available from: https://www.health.qld.gov.au/torres-cape/html/tuberculosis. 369 Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V, et al. Speaking the 32. 370 same language: treatment outcome definitions for multidrug-resistant tuberculosis. International 371 Journal of Tuberculosis and Lung Disease. 2005;9(6):640-5. 372 de Mendonça EB, Schmaltz CA, Sant'Anna FM, Vizzoni AG, Mendes-de-Almeida DP, et al. 33. 373 Anemia in tuberculosis cases: A biomarker of severity? PLOS ONE. 2021;16(2). 374 Simpson G. Multidrug-resistant tuberculosis on Australia's northern border. National Library 34. 375 of Medicine. 2011;41(11):759-61. 376 Falzon D, Mirzayev F, Wares F, Baena IG, Zignol M, Linh N, et al. Multidrug-resistant 35. 377 tuberculosis around the world: what progress has been made? European Respiratory Journal. 378 2015;45(1):150-60. 379 36. Torres and Cape Hospital and Health Service. Procedure: Management of Papua New Guinea 380 Nationals accessing healthcare within the Australian Islands of the Torres Strait Protected Zone, 381 presumed to have or diagnosed with tuberculosis. Torres and Cape Hospital and Health Service; 382 2017. 383 37. National Tuberculosis Advisory Committee. The Strategic Plan for Control of Tuberculosis in 384 Australia, 2016–2020: Towards Disease Elimination. The National Tuberculosis Advisory Committee 385 for the Communicable Diseases Network Australia Communicable Diseases Intelligence. 2018;2019(43):1-19. 386 387 38. Javaid A, Khan MA, Khan MA, Mehreen S, Basit A, Khan RA, et al. Screening outcomes of 388 household contacts of multidrug-resistant tuberculosis patients in Peshawar, Pakistan. Asian Pacific 389 Journal of Tropical Medicine. 2016;9(9):909-12.

medRxiv preprint doi: https://doi.org/10.1101/2022.03.22.22272751; this version posted March 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

390 39. Khan MA, Mehreen S, Basit A, Khan RA, Jan F, Ullah I. Characteristics and treatment 391 outcomes of patients with multi-drug resistant tuberculosis at a tertiary care hospital in Peshawar, 392 Pakistan. Saudi Medical Journal. 2015;36(12):1463.

393 Torres and Cape Hospital and Health Service. TB education in PNG treaty villages. Cairns, 40. 394 Queensland 2015.

395 41. Alene KA, Viney K, McBryde ES, Tsegaye AT, Clements ACA. Treatment outcomes in patients 396 with multidrug-resistant tuberculosis in north-west Ethiopia. Tropical Medicine & International 397 Health. 2016;22(3):351-62.

398 42. Baker MA, Harries AD, Jeon CY, Hart JE, Kapur A, Lönnroth K, et al. The impact of diabetes on 399 tuberculosis treatment outcomes: A systematic review. BioMed Central Medicine. 2011;9(81).

400 43. Viney K, O'Connor J, Wiegandt A. The epidemiology of tuberculosis in pacific island countries 401 and territories: 2000-2007. Asia Pacific Journal of Public Health. 2011;23(1):86-99.

402 Bates M, Marais BJ, Zumla A. Tuberculosis Comorbidity with Communicable and 44. 403 Noncommunicable Diseases. Perspectives in Medicine. 2015;11(6).

404 45. Marais BJ, Lönnroth K, Lawn SD, Migliori GB, Mwaba P, Glaziou P, et al. Tuberculosis 405 comorbidity with communicable and non-communicable diseases: integrating health services and 406 control efforts. Lancet Infectious Diseases. 2013;13:436-48.

407 46. Australian Department of Health. What we're doing about kidney disease Canberra, 408 Australia: Australian Department of Health. 2020 [Available from:

- 409 https://www.health.gov.au/health-topics/chronic-conditions/what-were-doing-about-chronic-410 conditions/what-were-doing-about-kidney-disease.
- 411 47. Australian Institute of Health and Welfare. Profiles of Aboriginal and Torres Strait Islander 412 people with kidney disease. Canberra, Australia: Australian Institute of Health and Welfare. 2020.

413 Report No.: 978-1-76054-712-7 Contract No.: Cat. no: IHW 229. 414 Chedid C, Kokhreidzec E, Tukvadze N, Banud S, Khaja M, Uddind M, et al. Association of 48.

415 baseline white blood cell counts with tuberculosis treatment outcome: a prospective multicentered 416 cohort study. International Journal of Infectious Diseases. 2020;100:199-206.

417 49. Panteleev AV, Nikitina IY, Burmistrova IA, Kosmiadi GA, Radaeva TV, Amansahedov RB, et al.

418 Severe Tuberculosis in Humans Correlates Best with Neutrophil Abundance and Lymphocyte

419 Deficiency and Does Not Correlate with Antigen-Specific CD4 T-Cell Response. Frontiers in 420 Immunology. 2017;21(8):963.

421 Kiran B, Cagatay T, Clark P, Kosar F, Cagatay P, Yurt S, et al. Can immune parameters be used 50. 422 as predictors to distinguish between pulmonary multidrug-resistant and drug-sensitive tuberculosis? 423 Archives of Medical Science. 2010;6(1):77-82.

424 51. Mehta JB, Fields CL, Byrd Jr RP, Roy TM. Nutritional status and mortality in respiratory failure 425 caused by tuberculosis. Journal of the Tennessee Medical Association. 1996;89(10):369-71.


426 52. Bendayan D, Hendler A, Polansky V, Weinberger M. Outcome of hospitalized MDR-TB 427 patients: Israel 2000–2005. European Journal of Clinical Microbiology and Infectious Diseases.

428 2011;30:375-9.

429 53. Nagu TJ, Spiegelman D, Hertzmark E, Aboud S, Makani J, Matee MI, et al. Anemia at the

430 Initiation of Tuberculosis Therapy Is Associated with Delayed Sputum Conversion among Pulmonary 431 Tuberculosis Patients in Dar-es-Salaam, Tanzania. PLOS ONE. 2014;9(3).

432





Figure